Mixed müllerian tumours of the endometrium. About four cases developed on tamoxifen treatment;Tumeurs mixtes müllériennes de l'endomètre. À propos de quatre cas développés sous tamoxifène

Gynecologie Obstetrique et Fertilite

Volumn 31, Issue 9, 2003, Pages 733-738

  Le Bouedec G ^a   Penault Llorca, F ^b   De Latour, M ^b   Tortochaux, J ^b   Dauplat, J ^a  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b Centre de Lutte Contre le Cancer Jean Perrin   (France)

Author keywords

Breast cancer; Mixed m llerian tumors; Tamoxifen

Indexed keywords

MEDROXYPROGESTERONE ACETATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER RISK; CASE REPORT; CELL TYPE; CLINICAL FEATURE; ECHOGRAPHY; ENDOMETRIUM CARCINOMA; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MIXED MULLERIAN TUMOR; POSTMENOPAUSE; TREATMENT OUTCOME; UTERUS SARCOMA;

EID: 0141794491     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/S1297-9589(03)00216-9     Document Type: Article

References (37)

1. Van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LALM, Gimbrère CHF, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52.
2. Sasco AJ, Ah-Song R, Gendre I, Zlatoff P, Bobin JY, et al. Cancer de l'endomètre et tamoxifène. Discussion à partir d'une série de cas. Bull Cancer 1997;84:51-60.
3. Lansac J, Diouf A. Comment surveiller une femme sous tamoxifene. J Gynecol Obstet Biol Reprod 1998;27:285-9.
4. Mourits MJE, De Vries EGE, Willemse PHB, Ten Hoor KA, Hollema H, Van der Zee AGJ. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001;97:855-66.
5. Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet 1988;2:563.Pelvic irradiation and tamoxifen as risk factor for carcinoma of corpus uteri. Lancet 1988;2:1432.
6. Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet 1988;2:563.Pelvic irradiation and tamoxifen as risk factor for carcinoma of corpus uteri. Lancet 1988;2:1432.
7. Magriples U, Naftolin F, Schwartz E, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11:485-90.
8. Clarke MR. Uterine malignant mixed mûllerian tumor in a patient on long-term tamoxifen therapy for breast cancer. Gynecol Oncol 1993; 51:411-5.
9. Evans MJ, Langlois NEI, Kitchener HC, Miller ID. Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Müllerian tumor), of the uterus? Int J Gynecol Oncol 1995;5:310-3.
10. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the national surgical adjuvant breast and bowel projet (NSAPB) B-14. J Natl Cancer Inst 1994;86:527-37.
11. McCluggage WG, McManus DT, Lioe TF, Hill CM. Uterine carcinosarcoma in association with tamoxifen therapy. Br J Obstet Gynaecol 1997;104:748-50.
12. Clément PB, Scully RE. Müllerian adenosarcoma of the uterus. A clinicopathologic analysis of ten cases of a distinctive type of müllerian mixed tumor. Cancer 1984;34:1138-49.
13. Peiffert D, Pernot M, Guillemin F, Luporsi E, Parache RM, Legras B, Bey P. Les tumeurs mixtes müllériennes de l'endomètre. Étude rétrospective, à visée pronostique, comparant leur évolution à celle des adénocarcinomes de l'endomètre. J Gynecol Obstet Biol Reprod 1991;20:933-40.
14. Bobin JY, Jaquot A, Lafont A, Rivoire M, Shisheboran M, Dolbeau D. L'adénosarcome utérin. À propos d'un cas. J Gynecol Obstet Biol Reprod 1993;22:245-8.
15. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237-8.
16. Bocklage T, Lee KR, Belinson JL. Uterine müllerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy. Gynecol Oncol 1992;44:104-9.
17. Altaras MM, Aviram R, Cohen I, Cordoba M, Yarkoni S, Beyth Y. Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas. Case report. Gynecol Oncol 1993;49:255-8.
18. Treilleux I, Mignotte H, Clement-Chassagne C, Guastalla P, Bailly C. Tamoxifen and malignant epithelial-nonepithelial tumours of the endometrium: report of six cases and review of the literature. Eur J Surg Oncol 1999;25:477-82.
19. Clément PB, Oliva E, Young RH. Müllerian adenosarcoma of the uterine corpus associated with tamoxifen therapy. Int J Gynecol Pathol 1996;15:222-9.
20. Barakat RR, Wong G, Curtin JP, Vlamis V, Hoskins WJ. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994;55:164-8.
21. McCluggage WG, Abdulkader M, Price JH, Kelehan P, Hamilton S, Beattie J, et al. Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases. Int J Gynecol Cancer 2000;10:280-4.
22. Varela-Duran J, Nochomovitz LE, Prem KA, Dehner LP. Postirradiation mixed müllerian tumors of the uterus. A comparative clinicopathologic study. Cancer 1980;45:1625-31.
23. Meredith RF, Eisert DR, Kaka Z, Hodgson SE, Johnston Jr GA, et al. An excess of uterine sarcomas after pelvic irradiation. Cancer 1986; 58:2003-7.
24. Thomas WO, Harris HH, Enden JA. Postirradiation malignant neoplasms of the uterine fundus. Am J Obstet Gynecol 1969;104:209-19.
25. Mignotte H, Lasset C, Bonadona V, Lesur A, Luporsi E, et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int J Cancer 1998;76:325-30.
26. Sasco A, Chaplain G, Amoros E, Satz S. Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy. Epidemiology 1996;7:9-13.
27. Deligdisch L, Kalir T, Cohen CJ, de Latour M, Le Bouëdec G, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 2000;78:181-6.
28. Seoud MAF, Johnson J, Weed JC. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol 1993;82:165-9.
29. Silva EG, Tornos CS, Follen-Mitchel M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol 1994;13:248-58.
30. Mourits MJE, Hollema H, Willemse PHB, de Vries EGE, Aalders JC, et al. Adenosarcoma of the uterus following tamoxifen treatment for breast cancer. Int J Gynecol Cancer 1998;8:168-71.
31. Friedrich M, Villena-Heinsen C, Mink D, Bonkhoff H, Schmidt W. Carcinosarcoma, endometrial intraepithelial carcinoma and endometriosis after tamoxifen therapy in breast cancer. Eur J Obstet Gynecol Reprod Biol 1999;82:85-7.
32. Arici DS, Aker H, Yildiz E, Tasyurt A. Müllerian adenosarcoma of the uterus associated with tamoxifen therapy. Arch Gynecol Obstet 2000; 264:105-7.
33. Dumortier J, Freyer G, Sasco AJ, Frappart L, Zenone T, Romestaing P, Trillet-Lenoir V. Endometrial mesodermal mixed tumor occurring after tamoxifen treatment: Report on a new case and review of the literature. Ann Oncol 2000;11:355-8.
34. Jessop FA, Roberts PF. Müllerian adenosarcoma of the uterus in association with tamoxifen therapy. Histopathology 2000;36:91-2.
35. Takai N, Fukuda J, Yoshimatsu J, Miyakawa I. Homologous carcinosarcoma of the uterine corpus associated with tamoxifen therapy. Int J Clin Oncol 2000;5:140-3.
36. Kaleli S, Calay Z, Altinok T, Kösebay D. Endometrial mixed müllerian tumor with heterologous elements following tamoxifen therapy for breast cancer: a case report and literature review. Eur J Obstet Gynecol Reprod Biol 2002;101:204-8.
37. Wickerham L, Fisher B, Wolmark N. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002;20:2758-60.